PCR

Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
PCR, Tuberculosis, COVID-19, Webcast, Research, EDT, Sale, Emergency Use Authorization, RSV, HPV, TB, FDA, Pharmaceutical industry

SALT LAKE CITY, March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023.

Key Points: 
  • SALT LAKE CITY, March 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023.
  • Full Year 2023 Financial Results:
    Revenue of $6.8 million, down from $34.2 million during the prior year primarily due to the decline in global demand for the Logix Smart® COVID-19 tests.
  • Co-Diagnostics plans to continue the development of our TB, multiplex respiratory, and HPV tests throughout the year," said Brian Brown, Co-Diagnostics' Chief Financial Officer.
  • Co-Diagnostics will host a conference call and webcast at 4:30 p.m. EDT today to discuss its financial results with analysts and institutional investors.

Discover the Latest in Sustainable Spouted Pouch and Cap Packaging Solutions with Cheer Pack NA at Expo West 2024

Retrieved on: 
Monday, March 11, 2024
PCR, Innovation Center station, Walking, SIOC, Food, LCA, Carbon, Marketing, Ship, CP

WEST BRIDGEWATER, Mass., March 11, 2024 /PRNewswire-PRWeb/ -- Discover the Latest in Sustainable Spouted Pouch and Cap Packaging Solutions with Cheer Pack NA at Expo West 2024

Key Points: 
  • Look for CPNA representatives walking the show floor or arrange a meeting time to learn more about the latest innovations in sustainable packaging solutions.
  • We are eager to engage with industry leaders at Expo West and showcase our latest sustainable packaging solutions...
  • Look for CPNA representatives walking the show floor or arrange a meeting time to learn more about the latest innovations in sustainable packaging solutions.
  • "We are eager to engage with industry leaders at Expo West and showcase our latest sustainable packaging solutions," said Al Madonna, Vice President of Marketing at Cheer Pack NA.

Cepheid Receives FDA Clearance for Xpert® Xpress GBS

Retrieved on: 
Monday, March 11, 2024
PCR, Obstetrics, Streptococcus, Rheumatic fever, EVP, INT, Risk, Cepheid variable, Antibiotic prophylaxis, Antimicrobial stewardship, Fungal infection, Genome, Woman, American College, GBS, Negative, ACOG, Infant, Food, Sintering

SUNNYVALE, Calif., March 11, 2024 /PRNewswire/ -- Cepheid announced today that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS). This next-generation test incorporates new dual targets in highly-conserved regions of the GBS genome to improve sensitivity and bacterial strain coverage. The test is designed for use on Cepheid's GeneXpert® systems.

Key Points: 
  • SUNNYVALE, Calif., March 11, 2024 /PRNewswire/ -- Cepheid announced today that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS).
  • Xpert Xpress GBS allows for the use of intrapartum direct PCR testing for women with unknown or unavailable antepartum GBS status.
  • With the capability of returning positive results as early as 30 minutes,2 Xpert Xpress GBS can provide real-time GBS status and inform decisions about empiric antibiotic prophylaxis if appropriate, to prevent GBS transmission during birth.
  • With Xpert Xpress GBS, Cepheid continues to provide fast, accurate, and reliable PCR solutions to facilitate evidence-based treatment and improved clinical care.

Microbix Unveils Test Controls for Head and Neck Cancer

Retrieved on: 
Monday, March 11, 2024
Woman, EQA, Sunnybrook Health Sciences Centre, QAP, TSX, Cancer, Throat, Exhibition, Dartmouth–Hitchcock Medical Center, IHC, Quality control, Mouth, Diagnosis, Tongue, Accreditation, Histology, Palate, Papillomaviridae, HPV, OTCQX, PCR, QC, Laboratory, Research, Nose, Head and neck cancer, Medical imaging

While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer in other bodily tissues.

Key Points: 
  • While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer in other bodily tissues.
  • Such further types of HPV-driven cancer include those of the “Head and Neck,” collectively tumours inside and behind the nose, throughout the mouth (including the tongue, gums, and palate), all sections of the throat, and the voice box.
  • Unfortunately, a lack of standardized and reproducible reference samples makes it challenging to control the recommended test workflows for diagnosing such cancers.
  • These standardized and reproducible tissue-oriented test controls will then be added to Microbix’s catalogue of QAPs, expanding its activities into support of oncology workflows alongside its wide range of infectious disease test controls.

HP Unveils Industry’s Largest Portfolio of AI PCs

Retrieved on: 
Thursday, March 7, 2024
Cloud, E60, NPU, Architecture, Comfort, G11, Travel, HPQ, Newsroom, News, Pro, HP EliteBook, Quantum, Software as a service, Organization, Ultra 5/10, Acceleration, Laptop, Central processing unit, USB, Data science, HP, ESC, Learning curve, HP Inc., Memory, GPU, AMD, HX, Microsoft, OEM, TEAMS, First officer (aviation), HP ZBook, VFX, Conference, LAS, Microsoft Teams, Creativity, PCR, NVIDIA, Workplace, AI, NGC, Work, Public sector, Risk, OS, Privacy, Fury, DGX, Wrist, Software

LAS VEGAS, March 07, 2024 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) today announced the industry’s largest portfolio of AI PCs1 leveraging the power of AI to enhance productivity, creativity, and user experiences in hybrid work settings.

Key Points: 
  • HP introduces the industry’s largest portfolio of AI PCs1, featuring new HP Elite PCs, the world’s most advanced business laptops for collaboration,2 and Z by HP mobile workstations to unlock new levels of productivity and creativity.
  • HP announces the AI Creation Center, the world’s most comprehensive workstation solution for AI development3, including Z by HP AI Studio co-engineered with NVIDIA NGC libraries, enabling AI creation.
  • HP now has the largest portfolio of Intel® and AMD-based AI PCs14, demonstrating a commitment to innovation and performance.
  • Accelerate data science capabilities with the HP AI Creation Center, including Z by HP AI Studio
    HP is accelerating the AI era with customized data science solutions.

Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing

Retrieved on: 
Monday, February 26, 2024
SAN, Hospital, NGD, OEM, Escherichia coli, Infection, NGS, Microfluidics, Life, WGS, Cefepime, Automation, Patient, Economics, Genomics, Standard BioTools, PCR, Laboratory, Partnership, Vaccine

Under the exclusive agreement, Standard BioTools™ will manufacture the NGD-100, a version of its microfluidics-based Biomark™ X9 System customized for NGD and optimized for automated pathogen WGS library preparation.

Key Points: 
  • Under the exclusive agreement, Standard BioTools™ will manufacture the NGD-100, a version of its microfluidics-based Biomark™ X9 System customized for NGD and optimized for automated pathogen WGS library preparation.
  • These systems will enable the cost efficiencies, flexibility and proven analytical performance that laboratories need to meet the increasing demands of pathogen testing.
  • “Standard BioTools’ microfluidics technology represents over 20 years of continuous refinement,” commented Michael Egholm, President and CEO of Standard BioTools.
  • “We have worked closely with NGD to develop this strategic partnership between our companies,” noted Alex Kim, Chief Operating Officer of Standard BioTools.

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

Retrieved on: 
Friday, March 8, 2024
Research, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Gene expression profiling, Breast cancer, Neoplasm, Taxane, Woman, Transcriptome, MD, MBCC, Cyclophosphamide, Anthracycline, PCR, MammaPrint, Risk, Conference, Symantec Endpoint Protection, AC-T, Patient, MP, Diagnosis, Triple-negative breast cancer, Blueprint, TC, Medical imaging

The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.

Key Points: 
  • The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.
  • ), investigates the associations between MammaPrint and BluePrint classifications, therapy regimen, and the likelihood of achieving a pathologic Complete Response (pCR).
  • The second poster, titled Prediction of chemotherapy benefit by MammaPrint® in patients with HR+HER2-early-stage breast cancer from real-world evidence studies (Audeh, W., et al.
  • Taken together, these findings indicate the utility of MammaPrint to predict neoadjuvant and adjuvant chemotherapy benefit in this patient population.

CleanNA launches CE-IVD product for quick and reliable viral DNA and RNA extraction

Retrieved on: 
Wednesday, March 6, 2024
Health, Medical Devices, Genetics, Research, Science, Pharmaceutical, Biotechnology, Bureau Veritas, DNA, COVID 19, RNA, RUO, PCR, COVID, Vaccine

The company’s Clean Quick Viral DNA/RNA (CE-IVD) extracts viral DNA and RNA from nasopharyngeal or oropharyngeal swab samples preserved in an inactivating viral transport medium.

Key Points: 
  • The company’s Clean Quick Viral DNA/RNA (CE-IVD) extracts viral DNA and RNA from nasopharyngeal or oropharyngeal swab samples preserved in an inactivating viral transport medium.
  • Clean Quick Viral DNA/RNA is based on magnetic beads, which makes the protocol easy to automate on CleanNA’s CleanXtract 96 or general liquid handlers.
  • CleanNA developed the Clean Quick Viral DNA/RNA for use in diagnostic workflows, that is why the product is CE-IVD marked.
  • “Clean Quick Viral DNA/RNA is the next CE-IVD marked product we launch in a short period of time.

Revolutionary Elephant iPSC Milestone Reached in Colossal’s Woolly Mammoth Project

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Technology, Health, Environmental Issues, Environmental Health, Other Science, Research, Software, Genetics, Environment, Science, Hoechst, KLF4, CRISPR, Woolly mammoth, Multimedia, Cattle, Growth, Harvard University, Cell, Developmental biology, TP53, Gametogenesis, Colossal Biosciences, Factorization of polynomials, Life, Elephant, IPSC, MYC, Cat, Genome, Gene, OCT4, Rhinoceros, Publication, PCR, Biology, Cancer, Hunting

Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.

Key Points: 
  • Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.
  • This milestone advancement was one of the primary early goals of the mammoth project, and supports the feasibility of future multiplex ex utero mammoth gestation.
  • Invaluable for Colossal’s Woolly Mammoths, these cells can be multiplex-edited and differentiated to study cold adaptation traits like woolly hair growth and fat storage in cellular and organoid models.
  • “In the past, a multitude of attempts to generate elephant iPSCs have not been fruitful.

Elevate Your Morning Ritual with Elmhurst 1925's Multi-Serve Lattes - Where Clean Ingredients and Rich Coffee Flavors Unite!

Retrieved on: 
Wednesday, February 28, 2024
Women, Fitness & Nutrition, Supermarket, Men, Family, Food, Beverage, Health, Consumer, Retail, Sprouts, Love, Kroger, Thrive Market, Erewhon, Multimedia, Steam, Carrageenan, Caffeine, Grain, ALA, The Fresh Market, Dietary fiber, Plant, Grain boundary strengthening, Ice, Orthodox Union Kosher, Milk, Tree, Coffee, Hydroelectricity, Amazon (company), Oil, Amazon, Bristol Farms, Recycling, SRP, PCR, FSC, Sprout, Vanilla, Water

Like all Elmhurst products, they contain minimal ingredients and are free from gums, oils and added fillers.

Key Points: 
  • Like all Elmhurst products, they contain minimal ingredients and are free from gums, oils and added fillers.
  • Plus, each 24 oz carton contains (2) 12 oz servings, so consumers can enjoy multiple lattes or share with a friend.
  • "This commitment to continuous innovation has led us to craft the ultimate dairy-free lattes for coffee lovers.
  • Unlike other plant-based lattes made with unnecessary preservatives, artificial flavors, carrageenan, gums, fillers, oils and emulsifiers, Elmhurst’s are crafted with only the simplest ingredients.